DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Toronto Dominion Bank

Toronto Dominion Bank lessened its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 118,166 shares of the medical device company’s stock after selling 6,136 shares during the quarter. Toronto Dominion Bank’s holdings in DexCom were worth $16,390,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in DXCM. Pacer Advisors Inc. increased its stake in shares of DexCom by 7.9% during the fourth quarter. Pacer Advisors Inc. now owns 55,174 shares of the medical device company’s stock valued at $6,847,000 after acquiring an additional 4,056 shares during the period. Washington Trust Advisors Inc. boosted its holdings in DexCom by 120.6% during the fourth quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock worth $44,000 after buying an additional 193 shares in the last quarter. Inscription Capital LLC bought a new stake in DexCom during the fourth quarter worth approximately $248,000. Caprock Group LLC boosted its holdings in DexCom by 2.2% during the fourth quarter. Caprock Group LLC now owns 17,993 shares of the medical device company’s stock worth $2,233,000 after buying an additional 382 shares in the last quarter. Finally, Gradient Investments LLC boosted its holdings in DexCom by 28.3% during the fourth quarter. Gradient Investments LLC now owns 152,839 shares of the medical device company’s stock worth $18,966,000 after buying an additional 33,742 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on DXCM shares. Royal Bank of Canada reduced their target price on shares of DexCom from $165.00 to $145.00 and set an “outperform” rating for the company in a report on Friday. Citigroup raised their target price on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Wells Fargo & Company reduced their target price on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating for the company in a report on Friday. Robert W. Baird cut shares of DexCom from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $161.00 to $80.00 in a report on Friday. Finally, UBS Group decreased their price objective on shares of DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a research note on Friday. Six investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $113.06.

Insider Activity

In other news, EVP Michael Jon Brown sold 659 shares of the firm’s stock in a transaction on Friday, June 28th. The shares were sold at an average price of $114.29, for a total transaction of $75,317.11. Following the transaction, the executive vice president now owns 66,901 shares in the company, valued at approximately $7,646,115.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Bridgette P. Heller sold 1,000 shares of DexCom stock in a transaction on Friday, June 14th. The shares were sold at an average price of $113.55, for a total value of $113,550.00. Following the transaction, the director now owns 25,349 shares in the company, valued at approximately $2,878,378.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael Jon Brown sold 659 shares of DexCom stock in a transaction on Friday, June 28th. The stock was sold at an average price of $114.29, for a total transaction of $75,317.11. Following the completion of the transaction, the executive vice president now owns 66,901 shares in the company, valued at approximately $7,646,115.29. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 4,112 shares of company stock worth $480,861. 0.30% of the stock is owned by corporate insiders.

DexCom Stock Down 40.7 %

Shares of NASDAQ:DXCM traded down $43.85 during trading on Friday, reaching $64.00. 53,844,273 shares of the company traded hands, compared to its average volume of 3,277,459. The firm has a fifty day simple moving average of $115.28 and a 200 day simple moving average of $123.83. The firm has a market cap of $25.45 billion, a P/E ratio of 41.29, a price-to-earnings-growth ratio of 2.74 and a beta of 1.16. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $1.04 billion. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The company’s revenue for the quarter was up 15.3% on a year-over-year basis. During the same quarter last year, the business posted $0.34 EPS. Analysts anticipate that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.